Connect with us

Press Release

FormBlends Launches the Most Comprehensive GLP-1 and Peptide Intelligence Platform on the Internet, Featuring 7,282 Provider Profiles and 100 Clinical Research Reports

Published

4 months ago

on

San Francisco, CA, April 9th, 2026 – FormBlends, a health technology platform focused on GLP-1 weight loss results and weight management provider directory listings, today announced the completion of a major platform expansion that positions it as the most comprehensive consumer intelligence resource for prescription weight management medications in the United States. The platform now features 7,282 individually profiled provider listings across all 50 states, 100 physician-reviewed clinical research reports, 17 interactive health tools, and a clinical education library covering every major GLP-1 and peptide therapy on the market.

As the $45 billion GLP-1 market accelerates toward $122 billion by 2030, FormBlends is building the definitive consumer resource for evidence-based medication information, provider transparency, and clinical education.

FormBlends: Building the most comprehensive GLP-1 and peptide intelligence platform on the internet

The announcement comes as the global GLP-1 receptor agonist market reaches $45.3 billion in 2025, projected to hit $122.3 billion by 2030.

Goldman Sachs forecasts the anti-obesity drug market at $95 billion by 2030. J.P. Morgan projects the global incretin market at $200 billion by the same year. Morgan Stanley estimates $77 billion.

1 in 8 American Adults

are currently taking a GLP-1 medication, with an additional 14% expressing interest in starting treatment. Monthly prescriptions for GLP-1 receptor agonists have grown from 700,000 to 2.6 million since 2021.

An Information Crisis in the Fastest-Growing Drug Category

The explosive growth of GLP-1 receptor agonist therapies has created an equally explosive information gap. The National Consumers League documented a 1,200% increase in “violative or problematic” GLP-1-related advertising between 2022 and 2024. Separately, the National Association of Boards of Pharmacy found that approximately 95% of websites offering prescription-only medications online operate outside of legal requirements, with 96% not requiring a valid prescription.

Harvard Medical School researchers have flagged social media as a primary vector for GLP-1 misinformation, with platforms like TikTok rampant with false claims about supplements and foods that supposedly replicate the effects of prescription medications. The FDA has issued multiple warnings about fraudulent products with false labeling entering the market.

“Patients are navigating an information environment where marketing is frequently disguised as medical advice,” said a FormBlends spokesperson. “The gap between what consumers need to know and what they can reliably find online is widening every month. We built this platform to close that gap with physician-reviewed, evidence-based clinical content.”

“We are not building a company that happens to have health content. We are building the most trusted clinical resource on the internet for GLP-1 and peptide therapy information, backed by peer-reviewed research and transparent provider data.”

What FormBlends Has Built: A Platform Overview

  1. The National Provider Directory. FormBlends now maintains 7,282 individually profiled weight management clinic listings across all 50 states, each featuring verified ratings, treatment offerings, pricing transparency data, patient review analysis, and an editorially written assessment. Unlike aggregator sites that scrape listings without context, every FormBlends profile includes editorial content reviewed by the platform’s medical team, honest advantages and limitations, and transparent cost comparison information. Provider data is sourced from the Yelp Fusion API and verified quarterly.
  2. Clinical Research Library. The platform’s research section houses 100 physician-reviewed reports covering GLP-1 receptor agonists, peptide therapies, and weight management science. Each report cites peer-reviewed sources from journals including the New England Journal of Medicine, JAMA, The Lancet, and Nature Medicine. FormBlends’ ambition is to function as the most complete reference library for GLP-1 and peptide clinical data on the internet, organized and explained for patients rather than clinicians.
  3. Interactive Health Tools. FormBlends offers 17 free clinical tools including a BMI calculator, drug interaction checker, insurance coverage checker, dosing schedule planner, peptide dosage calculator, and weight loss timeline estimator. These tools are designed to help patients prepare for conversations with their physicians, not replace medical consultation.
  4. Educational Article Library. The platform’s clinical education library includes comprehensive guides organized by drug class and therapeutic category. Article hubs cover GLP-1 receptor agonists, peptide therapy, medication comparisons, side effect profiles, dosing protocols, and cost analyses. Every article is medically reviewed and updated quarterly with current clinical data. All clinical claims cite peer-reviewed sources.

The Clinical Evidence: Why GLP-1 Medications Are Reshaping Medicine

The scale of FormBlends’ investment in clinical education reflects the extraordinary scope of what published research shows GLP-1 receptor agonists are capable of. These medications have demonstrated benefits extending well beyond weight management into cardiovascular disease, kidney disease, and metabolic health, representing what many researchers describe as the most significant pharmacological development in endocrinology in decades.

Clinical Trial Published Finding Source
STEP 1-4 14.9%-17.4% mean body weight loss at 68 weeks; 69-79% of patients achieved clinically meaningful weight reduction              NEJM, 2021
STEP 5 (Long-term) 16.7% sustained weight reduction maintained at 104 weeks vs. 0.6% with placebo Nature Medicine, 2022
SURMOUNT-1 22.5% weight reduction at highest dose; 63% of participants achieved 20% or greater reduction NEJM, 2022
SURMOUNT-5 (Head-to-Head)         Tirzepatide 20.2% vs. semaglutide 13.7% weight reduction at 72 weeks Applied Clinical Trials, 2025
SELECT (Cardiovascular) 20% reduction in major adverse cardiovascular events across 17,604 patients (HR 0.80) NEJM, 2023
FLOW (Kidney) 24% reduction in composite kidney endpoint; trial stopped early due to efficacy ADA, 2024

 

FormBlends’ research library provides detailed breakdowns of each of these trials, including a comprehensive semaglutide vs tirzepatide comparison, all translated from clinical language into patient-accessible explanations. The platform’s goal is to make published clinical data as accessible as possible, so patients can have informed conversations with their physicians about whether these therapies may be appropriate for their individual circumstances.

A $1.4 Trillion Problem

The economic burden of obesity in the United States is staggering. The Milken Institute and the GWU STOP Obesity Alliance estimate the total economic impact at $1.4 trillion annually when accounting for direct medical expenses and lost productivity.

Adults with obesity incur an average of $2,505 more in annual medical costs than normal-weight adults, with costs escalating to 233.6% higher for individuals with Class 3 obesity. US prescription drug spending hit $805.9 billion in 2024, up 10.2% year-over-year, with weight management medications accounting for 46.8% of the total increase.

Total US spending on GLP-1 receptor agonists grew over 500% from $13.7 billion in 2018 to $71.7 billion in 2023, according to a study published in JAMA Network Open.

$71.7 Billion

Total US GLP-1 receptor agonist spending in 2023, up from $13.7 billion in 2018. Weight management medications drove 46.8% of all US prescription drug spending growth in 2024.

Medicare Coverage: A Catalyst for Information Demand

Beginning July 1, 2026, Medicare will cover select GLP-1 receptor agonist medications for weight management at a $50 per month copay through the new “Medicare GLP-1 Bridge” program, marking the first-ever Medicare coverage for obesity medications after a two-decade exclusion. The CMS BALANCE Model, launching January 2027 for Medicare Part D, is projected to further expand access.

Goldman Sachs projects 15 million US adults will be on anti-obesity medications by 2030, representing 13% of the adult population excluding those with diabetes. J.P. Morgan’s estimate is higher: 25 million Americans by the same year.

“Medicare coverage will bring tens of millions of new patients into this category for the first time,” said a FormBlends spokesperson. “These patients will need reliable, physician-reviewed information to make informed decisions. That is exactly what our clinical resources and research library are designed to provide. We want to be the place physicians recommend their patients go to learn.”

The Peptide Frontier: Education Beyond GLP-1

FormBlends’ platform extends beyond GLP-1 receptor agonists into the broader peptide therapy landscape, which reached $140.86 billion globally in 2025 and is projected to grow to $260.25 billion by 2030 at a 10.77% CAGR.

The platform’s peptide education resources, dosage calculators, and reconstitution reference tools serve a growing consumer segment seeking evidence-based information about therapies gaining attention in longevity and regenerative medicine research. The platform’s retatrutide research hub covers next-generation triple-agonist GLP-1 therapies currently in late-stage clinical trials.

The Search for Answers: Consumer Behavior Signals Demand for Better Resources

Consumer search behavior reflects the intensity of demand for reliable GLP-1 information. The term “GLP-1” now averages over 3 million monthly Google searches, having surpassed “Ozempic” in search volume by early 2025 as consumers shift from brand-name awareness to drug-class research.

A longitudinal analysis published in PMC found that prescription volume and search volume for GLP-1 medications are correlated at r = 0.97, one of the highest correlation coefficients ever recorded between prescription drug utilization and online search behavior. This suggests that patients are actively researching these medications before and during treatment.

This behavioral shift signals a more sophisticated patient population, one that is no longer searching for a brand name from a television commercial but actively comparing clinical evidence, evaluating providers, and assessing costs before making treatment decisions. FormBlends’ provider comparison tools, head-to-head treatment analyses, and ranked provider guides are built specifically for this informed patient.

A New Face of Wellness

FormBlends’ thesis is that the GLP-1 era represents a fundamental shift in how Americans relate to their own health. For the first time, millions of people who were told that weight management was purely a matter of willpower have access to medications that address underlying biological mechanisms, medications backed by the largest, most rigorous clinical trial programs in modern endocrinology.

The company’s content philosophy reflects this shift. FormBlends does not position itself as a marketing platform. It provides clinical information, transparent provider data, and educational resources that allow patients to make decisions grounded in evidence rather than advertising. Every page on the platform, from the side effects guides to the provider directory to the health assessment, is reviewed by licensed clinicians and updated with current published data.

“For decades, the wellness industry sold aspiration. We are building something different: a platform that provides clarity. Patients deserve to know what these medications do, what the published clinical evidence shows, and where to find a qualified provider. If we do that well, the rest takes care of itself.”

“The consumer searching for GLP-1 information in 2026 is fundamentally different from the consumer who first typed ‘Ozempic’ into Google in 2023,” said a FormBlends spokesperson. “They are researching drug classes, reading published trial data, and comparing provider credentials before scheduling consultations. We built this entire platform for that patient.”

By the Numbers: FormBlends Platform as of April 2026

Platform Metric Value
Provider profiles maintained                               7,282 across all 50 states + D.C.
Clinical research reports 100 physician-reviewed
Interactive health tools 17 (free, no account required)
Educational articles 200+ medically reviewed guides
Drug classes covered GLP-1 receptor agonists, peptides, TRT
FAQs answered 72,820+ across directory and articles
Medical review process All content reviewed by licensed clinicians
Content update cycle Quarterly with latest published clinical data
Provider data source Yelp Fusion API, verified quarterly
Health assessment Free 2-minute online assessment


Availability

The FormBlends platform is available now at formblends.com. All educational content, research reports, interactive tools, and provider directory listings are free to access. Patients interested in exploring whether physician-supervised treatment may be appropriate for their circumstances can begin with a free health assessment.

About FormBlends

FormBlends is a health technology platform focused on GLP-1 receptor agonist education, peptide therapy research, and clinical health information. The platform combines the largest independently maintained weight management provider directory in the United States with interactive health tools, a peer-reviewed clinical research library, and physician-supervised telehealth consultations. All medical content is reviewed by licensed clinicians. Learn more at formblends.com.

Important Disclosures: This press release is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonist medications are prescription treatments that require evaluation by a licensed healthcare provider. Clinical trial results cited in this release refer to published, peer-reviewed studies of FDA-approved branded medications and may not be representative of outcomes with any other products. Individual results vary. Always consult a qualified healthcare professional before starting any prescription treatment. The FormBlends provider directory is an informational resource; inclusion does not constitute endorsement. Provider data is sourced from publicly available information and verified quarterly.

Media Contact

FormBlends Communications

Team@formblends.com

formblends.com/about

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Malaysia’s AI Future Takes Centre Stage as World AI Show Returns for Its 48th Global Edition

Published

14 hours ago

on

August 13, 2026

By

Kuala Lumpur, 13 August 2026, ZEX PR WIRE — Artificial intelligence has moved beyond being an emerging technology to become a defining pillar of Malaysia’s economic and digital ambitions. As the country accelerates investments in AI infrastructure, sovereign cloud capabilities, and enterprise-wide transformation, the focus has shifted from experimentation to execution. Against this backdrop, World AI Show Malaysia returns for its 48th Global Edition on 9–10 September 2026 at DoubleTree by Hilton Kuala Lumpur, Malaysia, convening the policymakers, enterprise leaders, technology pioneers, investors, and innovators who are shaping the country’s next chapter of AI-led growth. 

Presented by Trescon, World AI Show Malaysia carries this year’s tagline, “Where Malaysia’s AI Decisions Get Made.” As the country transitions into a strategic AI hub for Southeast Asia and organisations across both the public and private sectors define their AI roadmaps, modernise digital infrastructure, and establish governance frameworks for responsible innovation, the event will provide an executive platform dedicated to meaningful dialogue, strategic partnerships, and commercially relevant outcomes. 

The programme has been curated to address the opportunities and complexities surrounding enterprise AI adoption, sovereign cloud, intelligent infrastructure, cybersecurity, data governance, and responsible AI implementation. Over two days, attendees will engage through keynote addresses, executive panel discussions, fireside conversations, invitation-only boardroom sessions, technology showcases, curated networking engagements, and business meetings designed to facilitate knowledge exchange and cross-sector collaboration. 

The conference will feature an impressive line-up of distinguished government and industry leaders, including: 

  • Budiman Bujang, Deputy Chief Digital Officer, Johor Corporation 

  • Ts. D. Jackson Raao, Principal Assistant Secretary, Ministry of Science, Technology and Innovation (MOSTI) 

  • Jamie Tan, Managing Director, JLL Malaysia 

  • Ganeshbabu Nagarajan, Executive Director – Transformation Programmes, Standard Chartered Bank 

  • Chua Yong Howe, Chief Digital Officer, UEM Edgenta Berhad 

  • Shahrin Oli Mohamed, Group Chief Technology Officer, Pos Malaysia Berhad 

  • Keeratpal Singh, Chief AI and Data Officer (APAC Financial Services), Worldline 

  • Dr. Sadesh Manikam, Executive Vice President, Enterprise Data Office & Data Protection Officer, Bursa Malaysia 

  • Ts. Zairil Anuar Ahmad, Chief Technology Officer, Co-opbank Pertama 

  • Ahmad Faiz, Head – Data & AI, Global Technology Unit, BASF 

  • Raunak Mehta, Chief Executive Officer, Igloo 

  • Muhammad Najib Masdan, Senior Vice President, Khazanah Nasional Berhad 

  • Ts. Narayanan Chidambaram, Head Project Engineering Pod (Technology & Digital PE&T – Digital Project Management) PETRONAS 

  • Mohamed Aafrin, Director of Engineering, DKSH 

  • Sudeep Srivastava, Head – KL IT Center SLB (Schlumberger)  

  • Hong H. Ong, Director of Digital Technology, Labuan Financial Services Authority 

  • Mohd Hanapi Bisri, Senior Digital Industry Leader- Oil & Gas 

  • Dario Bianchi, Chief Product Officer, Mindvalley 

  • G Saravanan, Chief Information Officer, National Cancer Society Malaysia 

 

Reflecting on Malaysia’s AI trajectory, Ts. D. Jackson Raao, Principal Assistant Secretary, MOSTI, said: 

“Malaysia is at a pivotal stage where artificial intelligence is becoming a key driver of national transformation. As we accelerate AI adoption across industries, our focus must remain on responsible innovation, robust governance, strong cybersecurity, and developing a future-ready talent ecosystem. By doing so, Malaysia is well-positioned to emerge as a trusted regional leader in safe and sustainable AI innovation.”

An ecosystem of public sector and technology organisations is supporting this year’s edition. CyberSecurity Malaysia joins as the Supporting Partner, reinforcing the importance of building a secure and trusted digital ecosystem. 

Datadog joins as the Lead Sponsor, Magure as the Platinum Sponsor, Bitdeer AI as the Gold Sponsor, and Alibaba Cloud and Unison Consulting Sdn Bhd as Bronze Sponsors. The exclusive CXO Boardroom sessions will be powered by Zoom and Datadog, while CloudSpace will participate as an exhibitor, showcasing cloud and AI capabilities to enterprise decision-makers. 

Designed exclusively for senior executives, government representatives, and technology leaders, World AI Show Malaysia 2026 will provide a platform where strategic priorities are translated into actionable partnerships, investment opportunities, and real-world AI deployments. As Malaysia continues to strengthen its position within the regional AI landscape, the summit is set to become a key meeting point for organisations shaping the future of intelligent enterprise across Southeast Asia. 

CLAIM YOUR DELEGATE PASS:  Click here

For sponsorship opportunities, speaking engagements, or attendance information, please contact: 

Shrikanth Prabhu
Commercial Director 
Email: prabhu@tresconglobal.com 
Mobile: +91 8660115892

Media Contact: 
Reeha Haris 
Media & PR Executive
Email: reeha@tresconglobal.com 
Mobile: +91 8848655312 

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Phomemo Expands Tattoo Stencil Printer Solutions to Support Professional Artists Evolving Workflows

Published

14 hours ago

on

August 13, 2026

By

New York, New York, United States, 13th Aug 2026 – Phomemo, a global creative printing brand specializing in thermal printing solutions, has expanded its tattoo stencil printer lineup with two new solutions — the Phomemo TA81 Large-Format Tattoo Stencil Printer and Phomemo L85 Smart Touchscreen Tattoo Stencil Printer — designed to support the evolving needs of professional tattoo artists.

From large-scale body art preparation to everyday studio workflows, different tattoo projects require different printing solutions. While some artists prioritize portability and flexibility, others need tools that can handle full-length designs, customized layouts, and more efficient preparation processes.

Alongside established models including the M08F-WS and M08F Plus, Phomemo’s expanded tattoo printer lineup provides artists with multiple options based on their creative style, workflow, and studio needs.

Choosing the Right Tattoo Stencil Printer Matters

For tattoo artists, stencil preparation is an important step between digital design and the final artwork on skin. A reliable tattoo stencil printer can help artists maintain design accuracy, reduce preparation time, and create a smoother workflow before each session.

However, different tattoo styles create different challenges.

Artists specializing in fine details may prioritize clear and portable printing solutions, while those creating sleeves, back pieces, or large-scale compositions often face a different challenge: preparing oversized stencils without manually assembling multiple sections.

Phomemo’s tattoo stencil printer solutions are designed around these different creative scenarios.

Phomemo TA81: A Large-Format Tattoo Stencil Printer Built for Complex Designs

For artists who regularly create full sleeves, back pieces, legs, or other large-scale tattoo projects, stencil preparation can become one of the most time-consuming parts of the workflow.

Traditionally, oversized tattoo designs often require artists to print multiple stencil sheets, trim edges, align different sections, and carefully transfer the assembled design onto the skin. While this approach can work, maintaining accuracy across a large composition can add extra preparation steps and increase the risk of misalignment.

The Phomemo TA81 was designed to address this challenge with continuous, variable-length stencil printing.

Unlike standard sheet-based printing methods, the TA81 uses a roll-fed system that allows artists to print large tattoo designs in one continuous piece. For full sleeves, back pieces, spine designs, or other extended compositions, artists can create a complete stencil without manually cutting and joining multiple sections.

This one-piece printing workflow helps maintain design continuity and makes stencil preparation more efficient for complex tattoo projects.

Beyond size capability, the TA81 focuses on reducing waste during professional workflows. Its variable-length printing system allows artists to print only the required length for each design rather than relying on fixed-size sheets. For busy studios handling multiple projects, this can help optimize transfer paper usage during daily operations.

The TA81 also features Phomemo’s wrinkle-resistant printing technology, designed to help keep transfer paper flat during longer printing processes. Combined with an upgraded print head and edge-stabilizing design, the printer helps deliver consistent and clear stencil lines throughout the entire design.

With Bluetooth and USB connectivity support, the TA81 can connect with smartphones, tablets, laptops, and desktops across Android, iOS, Windows, macOS, and ChromeOS systems, giving artists flexibility when preparing designs.

Through the Phomemo App, artists can adjust designs, preview tattoo layouts, split large images, manage transfer settings, and prepare files before printing.

Phomemo L85: Smart Touchscreen Control for a More Customized Workflow

While large-scale artists may prioritize printing size and efficiency, other tattoo professionals look for a more interactive and customizable stencil preparation experience.

The Phomemo L85 is designed for artists who prefer a smarter workflow with direct control through an integrated touchscreen.

Featuring a 5-inch touchscreen with six language options, the L85 allows artists to manage printing tasks directly from the device. Functions such as template selection, brightness adjustment, print mileage tracking, battery information display, timer settings, sensor calibration, and self-testing can be accessed without relying entirely on another device.

For artists working with different tattoo styles and design formats, flexibility is also important. The L85 supports multiple print sizes, including Letter, A4, B5, A5, and additional width options, allowing artists to prepare different stencil layouts based on their projects.

The L85 also works with the Phomemo App ecosystem, providing creative and editing tools such as image transformation, tattoo extraction, line-art conversion, tattoo preview, and large-image splitting.

Optional AI-assisted features, including AI image generation and tattoo extraction, are designed to support artists during the preparation stage by helping explore ideas, refine concepts, and improve workflow efficiency — while keeping the artist’s own creativity and craftsmanship at the center of the design process.

Portable Tattoo Stencil Solutions: M08F-WS and M08F Plus

For artists who prioritize mobility, Phomemo also offers portable tattoo stencil printer solutions designed for flexible everyday workflows.

The Phomemo M08F-WS provides a lightweight wireless printing solution for artists who need a compact setup. Supporting Bluetooth connectivity and multiple operating systems, it allows artists to prepare tattoo stencils from smartphones, tablets, laptops, and desktops.

The Phomemo M08F Plus builds on this portable concept with a smarter touchscreen experience. Its built-in touchscreen supports functions including brightness adjustment, auto shutdown, calibration, and self-test printing, helping artists complete basic operations directly from the printer.

With thermal printing technology, both models eliminate the need for ink cartridges while providing a convenient solution for tattoo stencil preparation. Through the Phomemo App, artists can access editing tools, stencil generation, previews, and other workflow features designed to simplify the transition from digital artwork to physical stencil.

Choosing the Right Phomemo Tattoo Stencil Printer

Every tattoo artist has a different creative workflow, and the ideal tattoo stencil printer depends on the type of work being created. All can be found on Phomemo’s official site.

Artists working on large-scale compositions such as sleeves and back pieces may benefit from the Phomemo TA81’s continuous full-length printing capability.

Artists looking for a smart, customizable printing experience can explore the Phomemo L85 with touchscreen control and flexible print options.

Artists who need a portable solution for everyday stencil preparation can choose between the lightweight M08F-WS and the upgraded M08F Plus.

By developing tattoo stencil printers for different artistic scenarios, Phomemo continues to help tattoo professionals simplify preparation, improve efficiency, and focus more on the creative process.

About Phomemo

Phomemo is a global creative printing brand dedicated to making everyday printing simple, enjoyable, and accessible. Backed by over 12 years of expertise in thermal printing technology and trusted by over 40 million users worldwide, Phomemo continues to develop the evolution of smart printing. From home organization to global e-commerce, Phomemo lowers the barrier to professional results, enabling ideas and commerce to flow freely.

Media Contact

Organization: Phomemo

Contact Person: Alicia Chen

Website: https://phomemo.com

Email:
influencerscenter@phomemo.com

City: New York

State: New York

Country:United States

Release id:48084

The post Phomemo Expands Tattoo Stencil Printer Solutions to Support Professional Artists Evolving Workflows appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

SBCFX to Showcase Trading Innovation, Regional Growth Strategy, and Future Vision at iFX EXPO Asia 2026

Published

14 hours ago

on

August 13, 2026

By

Hong Kong, Hong Kong, August 13th, 2026, FinanceWire

SBCFX has announced its participation in iFX EXPO Asia 2026, one of the leading B2B exhibitions for the online trading, fintech, and financial services sectors. 

Scheduled to take place on 8–9 October 2026 at the Hong Kong Convention and Exhibition Centre (HKCEC), the event is expected to attract a diverse range of industry stakeholders, including brokers, traders, investors, Introducing Brokers (IBs), affiliates, fintech companies, liquidity providers, and financial services professionals from across Asia and beyond. 

As part of its ongoing international expansion strategy, SBCFX will showcase its integrated trading ecosystem, including the MetaTrader 5 (MT5) platform, multi-asset CFD trading capabilities, institutional-grade liquidity services, and its latest digital trading solutions. The company will also use the exhibition as a platform to share its growth strategy, technology roadmap, and long-term vision for the evolving global trading landscape. 

“iFX EXPO Asia represents an important opportunity for SBCFX to strengthen its engagement with the Asian trading community and further expand its regional network,” said David, CEO of SBCFX. 

“Our ambition is to become one of the most trusted global trading brands by bridging technology, education, and market access. We believe the future of online trading is not only about faster execution and better tools, but also about creating an ecosystem where traders, partners, and institutions can grow together. iFX EXPO Asia provides the perfect platform for us to share this vision and connect with the industry.” 

Driving Innovation While Building a Sustainable Trading Ecosystem 

Technology and innovation remain central to SBCFX’s long-term development strategy. The company continues to invest in digital infrastructure, trading technology, and client-focused solutions designed to enhance trading efficiency and improve user experience across global markets. 

Alongside its trading services, SBCFX will soon introduce a new mobile trading application that will provide clients with convenient access to account management, market information, trading tools, and platform services through a unified interface. The upcoming launch reflects the company’s ongoing efforts to improve accessibility and streamline the trading experience for users worldwide.   

Looking ahead, SBCFX remains focused on developing innovative solutions that support traders at every stage of their journey while strengthening connections between retail investors, institutional partners, and the broader financial ecosystem. By combining advanced technology with a client-centric approach, the company aims to create a smarter, more connected trading environment that adapts to the evolving needs of modern market participants. 

During the two-day event, SBCFX representatives will engage with prospective clients, Introducing Brokers, institutional partners, and technology providers to explore strategic collaborations and support the company’s continued growth across Asia. 

Meet SBCFX at Booth 37 

SBCFX welcomes individual traders, Introducing Brokers, affiliates, fintech firms, liquidity providers, institutional investors, and technology partners to visit Booth 37 and learn more about the company’s products, services, and strategic development plans. 

Visitors to the booth will have the opportunity to meet members of the SBCFX team, explore the company’s latest initiatives, and receive a selection of exclusive SBCFX promotional gifts and event merchandise available throughout the exhibition while supplies last. 

To facilitate more in-depth discussions and personalised consultations, attendees are encouraged to schedule a one-on-one meeting with the SBCFX team in advance via the following booking link: 

https://forms.cloud.microsoft/r/QwRd66ZmQa 

Event Details 

Event: iFX EXPO Asia 2026 

Date: 8–9 October 2026 

Time: 10:00 AM – 6:00 PM 

Venue: Hong Kong Convention and Exhibition Centre (HKCEC), Hong Kong 

Booth: 37 

For media enquiries or further information, please contact SBCFX at cs@sbcfx.com. 

About SBCFX 

SBCFX is a global financial services provider committed to delivering innovative online trading solutions supported by advanced technology, institutional-grade liquidity, and exceptional client service. Through continuous investment in technology, regulatory compliance, and strategic partnerships, SBCFX provides access to a wide range of global financial markets while empowering traders, Introducing Brokers, affiliates, and institutional partners to achieve long-term success. 

With a vision to become a trusted global brokerage, SBCFX remains dedicated to transparency, innovation, and sustainable growth, delivering world-class trading solutions to clients around the world. 

Contact

Marketing Executive
Kit Cheung
SBCFX
marketing@sbcfx.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us